Lead Sponsor

Novo Nordisk A/S

Age

All ages

Sex

ALL

Healthy Volunteers

No

•Male or female, aged 18-64 years (both inclusive) at the time of signing informed consent
•Body mass index (BMI) equal to or above 27.0 kg/m\^2
•Stable body weight (less than 3 kg self-reported change during the previous 3 months)
•Ultrasound assessment of gallbladder volume of an acceptable quality at screening, as judged by the investigator

•Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (intrauterine devices or hormonal contraception (oral contraceptive pills, implants, transdermal patches, vaginal rings or longacting injections))
•History of gastrointestinal surgery or other medical procedure precluding gallbladder emptying assessment (appendectomy is allowed) or any significant digestive disease per the judgement of the investigator
•History of pancreatitis (acute or chronic) or any gallbladder disease (incl. gallstones, gallbladder sludge, or polyps)
•Any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol

Related studies

NCT06894498 · Obesity and Obesity-related Medical Conditions, Weight Loss

NCT05124808 · Gestational Diabetes, Pregnancy, High Risk, and more

NCT06937086 · Ulcerative Colitis, Obesity or Overweight

NCT07595549 · Obesity, Overweight and/or Obesity, and more

NCT07284875 · Obesity, Overweight

A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.